New targets in advanced NSCLC: EML4-ALK

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 3, 2011, Pages 207-214

  Crystal, Adam S ^a   Shaw, Alice T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

ALK; Crizotinib; EML4 ALK; Lung cancer; NSCLC

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; AP 26113; CARBOPLATIN; CISPLATIN; CYSTEINE; DOCETAXEL; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 ANAPLASTIC LYMPHOMA KINASE FUSION PROTEIN; LEUCINE; METHIONINE; ONCOPROTEIN; PEMETREXED; PROTEIN KINASE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RESISTANCE; CIGARETTE SMOKING; DRUG EFFICACY; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; GENE FUSION; GENE IDENTIFICATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PERIPHERAL EDEMA; POINT MUTATION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TREATMENT RESPONSE; VISION;

CARCINOMA, NON-SMALL-CELL LUNG; GENE THERAPY; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PYRAZOLES; PYRIDINES;

EID: 79953241519     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. http://globo-can.iarc.fr. Accessed March 2, 2011.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Druker BJ, Talpaz M, Resta DJ, et al. Efcacy and safety of a specifc inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
4. Neal JW, Sequist LV. First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv Hematol Oncol. 2010;8:119-126.
5. Tatcher N, Chang A, Parikh P, et al. Geftinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-1537.
6. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919-8923.
7. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346.
8. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to geftinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311.
9. Mok TS, Wu YL, Tongprasert S, et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.
10. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med. 2004;350:2129-2139.
11. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science. 2004;304:1497-1500.
12. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of geftinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006;24:3340-3346.
13. Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of geftinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Torac Oncol. 2007;2:22-28.
14. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of geftinib as frst-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006;95:998-1004.
15. Morris SW, Xue L, Ma Z, Kinney MC. Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol. 2001;113:275-295.
16. Janoueix-Lerosey I, Lequin D, Brugières L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455:967-970.
17. Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol. 2000;156:1711-1721.
18. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68:3389-3395.
19. Grifn CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in infammatory myofbroblastic tumors. Cancer Res. 1999;59:2776-2780.
20. Soda M, Choi YL, Enomoto M, et al. Identifcation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.
21. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. Te biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46:1773-1780.
22. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifes oncogenic kinases in lung cancer. Cell. 2007;131:1190-1203.
23. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A. 2008;105:19893-19897.
24. Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3K/MEK and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010;70:9827-9836.
25. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10:298-302.
26. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15:5216-5223.
27. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16:1561-1571.
28. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to his-tological characteristics in a subset of lung cancers. J Torac Oncol. 2008;3:13-17.
29. Shinmura K, Kageyama S, Tao H, et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer. 2008;61:163-169.
30. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res. 2008;14:6618-6624.
31. Wong DW, Leung EL, So KK, et al. Te EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723-1733.
32. Martelli M P, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174: 661-670.
33. Takahashi, T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17:889-897.
34. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identifed by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15:3143-3149.
35. Yasuda H, Soejima K, Nakayama S, et al. Bronchoscopic microsampling is a useful complementary diagnostic tool for detecting lung cancer. Lung Cancer. 2010 Aug 31. Epub ahead of print.
36. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22:508-515.
37. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcrip-tional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40: 1152-1158.
38. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol. 2010;63:1066-1070.
39. Sakairi Y, Nakajima T, Yasufuku K, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res. 2010;16:4938-4945.
40. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247-4253.
41. Koivunen J P, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efcacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14: 4275-4283.
42. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010;9:188.
43. Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer. 2008;98:1536-1539.
44. Lin E, Li L, Guan Y, et al. Exon array profling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009;7: 1466-1476.
45. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defned by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28:4616-4620.
46. Kuo YW, Wu SG, Ho CC, Shih JY. Good response to geftinib in lung adeno-carcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Torac Oncol. 2010;5:2039-2040.
47. Shaw AT, Yeap B, Costa DB, et al. Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer (NSCLC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28:Abstract 7606.
48. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.
49. Camidge DR. Clinical activity of crizotinib (PF-02341066), in ALK-positive patients with non-small cell lung cancer (NSCLC). Presented at: 35th Congress of the European Society for Medical Oncology. Milan, Italy; October 8-12, 2010.
50. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734-1739.
51. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarci-nomas to geftinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.
52. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472-3475.
53. Zhang S, Wang F, Keats J, et al. AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Presented at the 101st American Association for Cancer Research Annual Meeting; April 17-21, 2010; Washington D.C. Abstract LB-298.